Have a feature idea you'd love to see implemented?
Let us know!
ARQT Arcutis Biotherapeutics Inc
Price (delayed)
$8.41
Market cap
$983.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.06
Enterprise value
$1.11B
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent
Highlights
ARQT's EPS has soared by 63% YoY and by 26% QoQ
Arcutis Biotherapeutics's net income has increased by 40% YoY and by 9% QoQ
Arcutis Biotherapeutics's equity has surged by 132% YoY but it has decreased by 17% QoQ
Arcutis Biotherapeutics's quick ratio has decreased by 15% QoQ
Key stats
What are the main financial stats of ARQT
Market
Valuations
Earnings
Shares outstanding
116.89M
Market cap
$983.05M
Enterprise value
$1.11B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.22
Price to sales (P/S)
7.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.37
Revenue
$132.06M
EBIT
-$165.11M
EBITDA
-$163.24M
Free cash flow
-$177.02M
Per share
Balance sheet
Liquidity
EPS
-$2.06
Free cash flow per share
-$1.43
Book value per share
$1.61
Revenue per share
$1.07
TBVPS
$3.55
Total assets
$444.76M
Total liabilities
$258.33M
Debt
$207.56M
Equity
$186.43M
Working capital
$383.24M
Debt to equity
1.11
Current ratio
8.46
Quick ratio
7.92
Net debt/EBITDA
-0.75
Margins
Efficiency
Dividend
EBITDA margin
-123.6%
Gross margin
92.3%
Net margin
-150.5%
Operating margin
-136.1%
Return on assets
-51%
Return on equity
-145.4%
Return on invested capital
-38.9%
Return on capital employed
-42%
Return on sales
-125%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARQT stock price
How has the Arcutis Biotherapeutics stock price performed over time
Intraday
0.72%
1 week
-11.38%
1 month
-13.12%
1 year
251.88%
YTD
160.37%
QTD
-9.57%
Financial performance
How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$132.06M
Gross profit
$121.91M
Operating income
-$179.77M
Net income
-$198.76M
Gross margin
92.3%
Net margin
-150.5%
The operating margin has soared by 95% YoY and by 26% from the previous quarter
Arcutis Biotherapeutics's net margin has surged by 95% YoY and by 26% QoQ
The company's operating income rose by 43% YoY and by 8% QoQ
Arcutis Biotherapeutics's net income has increased by 40% YoY and by 9% QoQ
Growth
What is Arcutis Biotherapeutics's growth rate over time
Valuation
What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
5.22
P/S
7.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.37
ARQT's EPS has soared by 63% YoY and by 26% QoQ
Arcutis Biotherapeutics's equity has surged by 132% YoY but it has decreased by 17% QoQ
The stock's price to book (P/B) is 11% more than its 5-year quarterly average of 4.7 and 2.4% more than its last 4 quarters average of 5.1
The company's revenue rose by 24% QoQ
The price to sales (P/S) is 6% higher than the last 4 quarters average of 7.4
Efficiency
How efficient is Arcutis Biotherapeutics business performance
ARQT's ROS has soared by 95% YoY and by 28% QoQ
The company's return on invested capital rose by 37% YoY and by 17% QoQ
ARQT's return on assets is up by 36% year-on-year and by 16% since the previous quarter
The ROE has grown by 26% from the previous quarter and by 23% YoY
Dividends
What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARQT.
Financial health
How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 72% greater than its total liabilities
ARQT's total assets is up by 39% year-on-year but it is down by 7% since the previous quarter
Arcutis Biotherapeutics's quick ratio has decreased by 15% QoQ
Arcutis Biotherapeutics's debt is 11% higher than its equity
Arcutis Biotherapeutics's equity has surged by 132% YoY but it has decreased by 17% QoQ
ARQT's debt to equity has dropped by 56% year-on-year but it is up by 21% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.